Search - tctmd.com

Displaying 481 - 500 of 501

Sort: Relevancy | Date

News Daily News

Community Death Rates Following Type 2 MI Speak to Lack of Treatments, Trials

Yael L. Maxwell

January 10, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

hs-Troponin Fails to ID Ischemia in Symptomatic Stable CAD

Todd Neale

January 10, 2020

News Daily News

Diabetes Does Not Appear to Hinder FFR Insights for CAD

Caitlin E. Cox

January 09, 2020

News Daily News

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

Michael O'Riordan

January 08, 2020

News Daily News

FFR Can Safely Guide PCI Deferral, With Solid Long-term Results: J-CONFIRM

Caitlin E. Cox

January 03, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

SCAI Experts Update Transradial Guidance

Yael L. Maxwell

January 03, 2020

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

January 02, 2020

News Features

TCAR’s Rise Is Shaking Up Carotid Stenosis, but Dependable Data Lag Behind

Todd Neale

January 02, 2020

News Opinion Editor's Corner

The Biggest News of 2019: TCTMD’s Top 10

Shelley Wood

January 01, 2020

Presentation Controversies and Advances 2019

Should TAVR Be Standard for Bicuspid Aortic Stenosis, Or Do We Need a Randomized Clinical Trial?

Presenter: Raj R. Makkar

November 15, 2019

Presentation Cardiovascular Interventions 2019

Show me the Data: Key Clinical Trials of 2019

Presenter: Ehtisham Mahmud

November 01, 2019

CME

Latest Data in Renal Denervation

Partner Content

COVID-19 TCTMD HUB

July 17, 2020

BIO

Keith C. Ferdinand

CME

Optimizing the Duration of DAPT following PCI

CME

Advertisement

Community Death Rates Following Type 2 MI Speak to Lack of Treatments, Trials

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

hs-Troponin Fails to ID Ischemia in Symptomatic Stable CAD

Diabetes Does Not Appear to Hinder FFR Insights for CAD

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

FFR Can Safely Guide PCI Deferral, With Solid Long-term Results: J-CONFIRM

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

SCAI Experts Update Transradial Guidance

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

TCAR’s Rise Is Shaking Up Carotid Stenosis, but Dependable Data Lag Behind

The Biggest News of 2019: TCTMD’s Top 10

Should TAVR Be Standard for Bicuspid Aortic Stenosis, Or Do We Need a Randomized Clinical Trial?

Show me the Data: Key Clinical Trials of 2019

Latest Data in Renal Denervation

COVID-19 TCTMD HUB

Keith C. Ferdinand

Optimizing the Duration of DAPT following PCI

Optimization of Clinical Pathways for Treating Low Risk Patients with severe AS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content